The influence of ethnicity on warfarin dosage requirement. - Wikidata - awgldk - TriplyDB

The influence of ethnicity on warfarin dosage requirement.

The influence of ethnicity on warfarin dosage requirement.

http://www.wikidata.org/entity/Q46458606

about

Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin Increased genetic diversity of ADME genes in African Americans compared with their putative ancestral source populations and implications for pharmacogenomics.Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.The future prospects of pharmacogenetics in oral anticoagulation therapy.Evaluation of a required senior research project in a doctor of pharmacy curriculum.Influence of ethnic origin and sex on the pharmacokinetics of clazosentan.Relationship between the Occurrence of Thromboembolism and INR Measurement Interval in Low Intensity Anticoagulation after Aortic Mechanical Valve Replacement Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: is there a treatment disparity?Effects of VKORC1 Genetic Polymorphisms on Warfarin Maintenance Dose Requirement in a Chinese Han Population.Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?Pharmacogenetics of chronic cardiovascular drugs: applications and implications.Effect of patient-specific factors on weekly warfarin dose Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans Use of genetic and nongenetic factors in warfarin dosing algorithms.Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.Atrial Fibrillation and Race - A Contemporary Review.Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.Patient factors that influence warfarin dose response.New oral anticoagulants in practice: pharmacological and practical considerations.Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials.Warfarin Pharmacogenomics in Diverse Populations.Prediction of biogeographical ancestry from genotype: a comparison of classifiers.Drug Treatment of Venous Thromboembolism in the Elderly.Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review.Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements.Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors.Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism.Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.The need for multicentre cardiovascular clinical trials in Asia.Vitamin K epoxide reductase complex 1 (VKORC1) haplotypes in healthy Hungarian and Roma population samples.VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.Establishing an oral anticoagulant monitoring service in a multiethnic developing country.Shifting paradigms in the pharmacogenetics of warfarin.Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort.The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations.Pharmacokinetics and tolerability of almorexant in Japanese and Caucasian healthy male subjects.

P2860

Q24814457-3E899F48-D25B-4681-880D-542F63B2563F Q28276514-A5CAC230-A377-4B63-863A-36814AD2CFF3 Q33613526-0A7860F8-331B-4B5A-95EE-6786D5D45194 Q33770184-0F768D0C-C12E-4D9E-8DDF-C5DDE1487653 Q34096562-186EC6B5-47A5-4A32-8BA1-3FA2E23B31BA Q34530230-CF532F9D-67B2-4721-B133-843469EEC827 Q34628256-36833941-706D-4000-9727-A65B59D26A16 Q34655124-DCEB3A01-3F60-4F5D-842D-71B0ABF2F970 Q35644607-B865B0BD-DB2C-40E9-8113-5210A93EF9D3 Q35654365-BA47E8F3-73A7-47FE-9BAF-B4B063077F4A Q36314728-EEB6DF29-F5C1-494A-8FE6-12C21AD8778B Q36487290-359B48CC-56B5-43DF-B7AB-2F16DD4E9489 Q36543128-8074FFFB-46B8-46EC-B0F3-82E4B8C19B5C Q36661285-86224617-87AF-47DD-8F84-24EAFFE01C9A Q36835168-5476A837-8037-4138-B2E5-9BA978CB5180 Q36982736-57393066-9DC9-421A-B1D2-694559DCB4E3 Q37074097-1F2CA1B8-53B2-45F3-A07B-8C2EEC0D911B Q37264555-F3277327-103A-4578-854A-6062F9F4805A Q37274009-4AA0E897-4D3C-4D77-B3E7-8F4129C380FA Q37276490-E0D78215-1F1D-4F65-82E9-4CE0F92A7F22 Q37376879-E31BA8CE-3BFA-4B69-B040-9F365015888D Q37867275-CBEF62B0-DC4C-4068-94EA-0D030197FADF Q38180988-D3476943-265F-44AE-BC4B-074EF2E638B7 Q38264260-146CE7E4-82C1-4340-9C08-1F3933C5ED97 Q38696567-F7A3EE27-BAAF-4D6E-B7AF-76F4D29428A5 Q38725359-455A9E69-6CFF-4682-80EF-96963C62C5F5 Q38851927-5845B4BF-7336-4261-B8C5-DFFA9D3AB123 Q38958252-FFFFFEEF-581E-4F4B-9E71-2C047DAA1328 Q39862947-8C7C702B-A31E-4982-B36A-5C21B351FB17 Q40285992-D98AC9E3-63F0-4285-BBB6-7908B06E2DEB Q42722363-439D4DF7-58A2-4EA8-8968-293FC66834E6 Q42791847-4887A322-1700-4CEB-8CF1-BD08B30DFC0A Q43609145-DD12C7C5-89FF-4326-A309-9B2F9F39F23C Q45749835-F9531D39-10FB-4F63-9CD8-6C43F66037FB Q46238853-E82150F6-14AF-4458-B621-C61F1E075508 Q46265412-520CF31E-78BE-473D-A3F0-A721680B1F23 Q46316268-56447F46-D213-42EC-B544-6493A733C2E3 Q46466680-D0209658-0D97-4576-8B73-B3E31A36C02B Q46573199-93AA8A75-D45F-4619-AF50-F7336257618E Q46862790-0E063140-9804-47F8-B355-C42EC3D89FE7

P2860

The influence of ethnicity on warfarin dosage requirement.

http://www.wikidata.org/entity/Q46458606

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

The influence of ethnicity on warfarin dosage requirement.

@en

The influence of ethnicity on warfarin dosage requirement.

@nl

type

label

The influence of ethnicity on warfarin dosage requirement.

@en

The influence of ethnicity on warfarin dosage requirement.

@nl

prefLabel

The influence of ethnicity on warfarin dosage requirement.

@en

The influence of ethnicity on warfarin dosage requirement.

@nl

P1433

Q46458606-D16168F5-3FA0-49EC-A634-2352283B3653

P1476

Q46458606-5125C54B-9A1A-435F-A3A3-3EA5EB6BE8FC

P2093

Q46458606-00C43188-BD71-4D80-B47D-8DD22E74BEB4

Q46458606-17F6FF24-734D-4C64-9274-71991260D9B5

Q46458606-360FB630-BA09-4C7E-A22B-1080F28B6465

P2860

Q46458606-0A8F4CDD-11E0-4089-B31F-06A756B43C92

Q46458606-0EEAC3EA-82EC-4143-9933-2BF823BC923D

Q46458606-103C0D2E-ED7D-46B0-B698-6B18B6BBB17B

Q46458606-208C8005-3DEA-41EE-AE09-32A4AAE47649

Q46458606-220C28FC-7F0D-4099-A6B4-CCFA0BD8AE3D

Q46458606-2588A12A-1860-4D3D-9F9D-467189FB9EC9

Q46458606-409E3CB8-A54E-40FB-BE0D-53069CA2927B

Q46458606-492EE202-3AC8-4A32-9695-0BA64B84357E

Q46458606-55B3B092-20A8-4FB5-8C72-0FC979AC2408

Q46458606-5DDF8816-5657-4AEB-8C3C-24DF57F7DBAB

P304

Q46458606-A47CEDEC-6F32-46CE-B3CE-49A572739262

P31

Q46458606-D84D0A29-131E-4D1B-AAE9-7D7F972D3A29

P356

Q46458606-255C65FF-7369-4531-8979-6BA38E52F18D

P407

Q46458606-F07C22B3-B771-4D5D-BDB9-E5722169238A

P433

Q46458606-A07E0607-04FD-49A4-9FF2-76A32CC2EB2D

P478

Q46458606-5C5954E8-ADB6-4133-A385-06CE4B69DA56

P577

Q46458606-DF02F3F2-9F7C-4215-A42B-4DDC5184AA03

P5875

Q46458606-822FF2E4-C887-4114-89DF-AEE13A3815E2

P698

Q46458606-6FC5613A-580A-4B94-95A6-0AA0635178A6

P356

P1433

Annals of Pharmacotherapy

P1476

The influence of ethnicity on warfarin dosage requirement.

@en

P2093

Julie Hambleton

http://www.w3.org/2001/XMLSchema#string

Mai-Trang N Dang

http://www.w3.org/2001/XMLSchema#string

Steven R Kayser

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site

Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.

Long-term treatment with warfarin in Chinese population.

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

Factors affecting the maintenance dose of warfarin.

Aging and the anticoagulant response to warfarin therapy.

Interindividual variability in sensitivity to warfarin--Nature or nurture?

Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.

Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy.

Patient-specific factors predictive of warfarin dosage requirements.

P304

1008-1012

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1E566

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7883256

http://www.w3.org/2001/XMLSchema#string

P698

15855242

http://www.w3.org/2001/XMLSchema#string